Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Weilong Zhang, Yinghua Lv, Juan Yang, Yunhui Chen, Yingchun He & Jihan Huang. (2020) Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19. Drug Design, Development and Therapy 14, pages 3803-3813.
Read now
Read now
Katya C Corado, Margaret R Caplan & Eric S Daar. (2018) Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. Drug Design, Development and Therapy 12, pages 3731-3740.
Read now
Read now
Eugènia Negredo & Bonaventura Clotet. (2018) Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1. Expert Opinion on Pharmacotherapy 19:8, pages 929-934.
Read now
Read now
Margaret R. Caplan, Eric S. Daar & Katya C. Corado. (2018) Next generation fixed dose combination pharmacotherapies for treating HIV. Expert Opinion on Pharmacotherapy 19:6, pages 589-596.
Read now
Read now
Articles from other publishers (6)
Andrea Antinori, Alessandra Vergori, Diego Ripamonti, Daniela Valenti, Giuliano Rizzardini, Maria Vittoria Cossu, Stefano Rusconi, Vincenzo Esposito, Antonio Cascio, Giancarlo Orofino, Massimo Andreoni, Elio Manzillo, Antonella Castagna, Daniela Mancusi, Roberta Termini, Marianna Portaro & Alessia Uglietti. (2023) Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study. Future Virology 18:8, pages 479-488.
Crossref
Crossref
Hannes Lengauer, Damjan Makuc, Damjan Šterk, Franc Perdih, Arthur Pichler, Tina Trdan Lušin, Janez Plavec & Zdenko Časar. (2020) Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates. Pharmaceutics 12:4, pages 342.
Crossref
Crossref
Cristina Gómez Ayerbe, Jesús Santos González & Rosario Palacios Muñoz. (2018) Symtuza (DRV/c/FTC/TAF) en el tratamiento de inicio. Enfermedades Infecciosas y Microbiología Clínica 36, pages 17-21.
Crossref
Crossref
Betty J. Dong. (2018) HIV-1 update 2018. Pharmacy Today 24:10, pages 51-69.
Crossref
Crossref
Erik De Clercq. (2018) Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochemical Pharmacology 153, pages 2-11.
Crossref
Crossref
Eric S. Daar. (2017) Novel approaches to HIV therapy. F1000Research 6, pages 759.
Crossref
Crossref